JGC
EPZM

J. Goldman & Co’s Epizyme, Inc EPZM Stock Holding History

J. Goldman & Co’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-370,454
Closed -$3.82M – 380
2019
Q3 		$3.82M Buy
+370,454
New +$4.67M 0.29% 103
2017
Q1 		– Sell
-155,049
Closed -$1.88M – 436
2016
Q4 		$1.88M Buy
155,049
+75,049
+94% +$783K 0.12% 178
2016
Q3 		$787K Buy
+80,000
New +$730K 0.04% 251

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KXA
KPCB XIII Associates Menlo Park, California $186M AUM 11.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

J. Goldman & Co's EPZM Position: Q4 2019 in Review

J. Goldman & Co sold out of Epizyme, Inc (EPZM) in Q4 2019, closing a stake of 370,454 shares — an estimated $3.82M sold.

J. Goldman & Co first reported a position in EPZM in Q3 2016 and held it in 3 quarters. The position peaked at $3.82M in Q3 2019. 136 funds tracked by Wall St. Rank hold EPZM as of Q4 2019.

  • J. Goldman & Co reported no remaining Epizyme, Inc position as of Q4 2019 after selling out during the quarter.
  • J. Goldman & Co sold 370,454 Epizyme, Inc shares in Q4 2019, an estimated $3.82M.
  • J. Goldman & Co first reported a position in Epizyme, Inc in Q3 2016 and held it in 3 quarters.
  • J. Goldman & Co's Epizyme, Inc position peaked at $3.82M in Q3 2019.
  • 136 funds tracked by Wall St. Rank held Epizyme, Inc as of Q4 2019.

Based on J. Goldman & Co's 13F filing for Q4 2019, filed 14 Feb 2020.